Evidence map›Paper›PMID 42670840›Full record

ArticleJournal of chemical information and modeling2026

From Ternary Modeling to Predictive PROTAC Design: A Computational Perspective.

Joseph M Schulz, Robert C Reynolds, Stephan C Schürer

Abstract read
In one paragraph

Article in Journal of chemical information and modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Joseph M SchulzDepartment of Molecular and Cellular Pharmacology, University of Miami, Miami, Florida33124, United States.ORCID 0000-0001-7276-1835
Robert C ReynoldsO'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama35205, United States.ORCID 0000-0001-9413-2247
Stephan C SchürerDepartment of Molecular and Cellular Pharmacology, University of Miami, Miami, Florida33124, United States.

Funding

Tumor Biology Research ProgramP30CA240139 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Stephen D. Nimer · 2019 to 2026
$24.1M
Unifying Templates, Ontologies and Tools to Achieve Effective Annotation of Bioassay ProtocolsU01LM012630 · NLM · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BUNIN, BARRY A, MUSEN, MARK A · 2017 to 2020
$2.1M
Congressionally Directed Medical Research Programs 1420842Florida Department of Health 23B16NCI NIH HHS P30 CA240139NLM NIH HHS U01 LM012630U.S. National Library of Medicine U01 LM012630
6 · The paper itself

Abstract

Proteolysis-targeting chimeras (PROTACs) are heterobifunctional small molecules that induce targeted protein degradation by recruiting an E3 ligase to a protein of interest. Since 2019, publication volume has accelerated, and computational methods have expanded from isolated demonstrations into practical tools for modeling PROTAC-induced ternary complexes, designing linkers, and forecasting degradation-related outcomes. Here, we present a Perspective on computational PROTAC methodologies published from 2019 to the present, organizing the field into two complementary streams: (i) constraint-driven, physics-based workflows that assemble and refine ternary complex models by enforcing geometric feasibility and evaluating pose stability using docking and molecular simulation; and (ii) data-driven workflows, including deep learning predictors and generative models that predict ternary complex structure, degradation end points, or linker chemistry from structural and assay data. We highlight representative approaches spanning restrained/tethered docking, MD-based refinement and dynamic stability scoring, coarse-grained free-energy modeling, SE(3)/E(3)-equivariant structure prediction, supervised degradation efficacy prediction, and generative linker design. We close by emphasizing persistent gaps, fragmented benchmarking, score robustness across targets and E3 ligases, and nonstandard molecular representations that currently limit generalization and reproducible, pipeline-ready deployment.

Indexed as

Drug DesignProteolysis Targeting ChimeraMolecular Docking SimulationMolecular Dynamics SimulationProteolysis Targeting Chimera

Identifiers

PMID42670840
PMCPMC13508781

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.